Objective: With this analysis we aimed to study the role of insomnia (both sleep onset and sleep maintenance insomnias) in Parkinson’s disease (PD) in relation to levodopa dose, treatment and disease duration,  and other related variables.

Background: Sleep disturbances are among the most common nonmotor comorbidities of Parkinson’s disease (PD). The most common PD-associated disturbances in sleep include sleep onset (SOI) and sleep maintenance insomnia (SMI) resulting in inefficient sleep and low daytime performance.

Method: PD was diagnosed using UK PDS Brain Bank criteria and assessed by UPDRS scale and Hoehn&Yahr (H&Y). Insomnia diagnosis was based on patients’ and caregivers’ interview. Two groups were formed according to presence of insomnia. Mann Whitney U test was used for statistical analysis.

Results: Sample description: n=154, mean age=64.2 years (43-87), females=48.7%. UPDRS and H&Y profile of the patients are presented in Table 1. PD patients reported insomnia in 62.9% of cases. Mean age, sex, BMI and age of PD onset were similar for both groups. Levodopa (LD) descriptives are presented in the Table 2. Disease duration and duration of LD treatment were significantly longer in patients with insomnia (p<0.05). LD total daily dose and doses per day were higher in patients with insomnia (p<0.05). Levodopa dose effect duration tended to be longer in insomnia patients (p>0.05).

Conclusion: Our results show high prevalence of insomnia in PD patients. PD patients with insomnia had longer disease and treatment duration, also LD dose and doses per day were higher in PD patients with insomnia. And interestingly LD dose effect duration tended to be longer in insomnia patients.

Disclosure: Nothing to disclose.

« Back to 2024 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/association-of-insomnia-with-levodopa-related-parameters-in-parkinsons-disease/